Tranexamic acid 1% mouthwash
Requires a prescription from a doctor or prescriber
Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Tranexamic acid
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Tranexamic acid
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(13)
Blood transfusion (NG24)
Joint replacement (primary): hip, knee and shoulder (NG157)
Blood transfusion (QS138)
Joint replacement (primary): hip, knee and shoulder (QS206)
Head injury: assessment and early management (NG232)
Abdominal aortic aneurysm: diagnosis and management (NG156)
Major trauma: assessment and initial management (NG39)
Heavy menstrual bleeding: assessment and management (NG88)
Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management (NG228)
Drainage, irrigation and fibrinolytic therapy (DRIFT) for post-haemorrhagic hydrocephalus in preterm infants (HTG276)
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)
Hemosep for cell salvage (MIB103)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 32 · Randomised trials: 18 · 1996–2026
Showing the 50 most relevant studies, sorted by most relevant.
Roberto Picetti, Haleema Shakur‐Still, Robert L. Medcalf, et al.
Blood Coagulation & Fibrinolysis, 2018
- Antifibrinolytic Agents
- Fibrinolysis
- Postpartum Hemorrhage
Yale A. Fillingham, Dipak B. Ramkumar, David S. Jevsevar, et al.
The Journal of Arthroplasty, 2018
- Arthroplasty, Replacement, Knee
- Network Meta-Analysis
- Antifibrinolytic Agents
Yale A. Fillingham, Dipak B. Ramkumar, D. Jevsevar, et al.
The Journal of arthroplasty, 2018
- Network Meta-Analysis
- Antifibrinolytic Agents
- Blood Transfusion
Shuhei Murao, Hidekazu Nakata, Ian Roberts, et al.
Critical Care, 2021
- Antifibrinolytic Agents
- Hemorrhage
- Tranexamic Acid
Katharine Ker, Phil Edwards, Pablo Perel, et al.
BMJ, 2012
- Antifibrinolytic Agents
- Blood Transfusion
- Myocardial Infarction
Mohamed Sukeik, Sattar Alshryda, Fares S. Haddad, et al.
Journal of Bone and Joint Surgery - British Volume, 2011
- Arthroplasty, Replacement, Hip
- Antifibrinolytic Agents
- Blood Transfusion
Sattar Alshryda, Mohamed Sukeik, Praveen Sarda, et al.
The Bone & Joint Journal, 2014
- Administration, Topical
- Antifibrinolytic Agents
- Blood Transfusion
Katharine Ker, David Prieto‐Merino, Ian Roberts
British journal of surgery, 2013
- Antifibrinolytic Agents
- Regression Analysis
- Tranexamic Acid
Lin Zhang, Zou Xiaoyi
Seizure, 2016
- Antifibrinolytic Agents
- Seizures
- Tranexamic Acid
Yale A. Fillingham, Dipak B. Ramkumar, David S. Jevsevar, et al.
The Journal of Arthroplasty, 2018
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
2 hours
Mechanism
Tranexamic acid competitively and reversibly inhibits the activation of plasmino…
Food interactions
1 warning
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
30 to 50%
[L31858]…
Half-life
2 hours
[L31858]…
Protein binding
3%
Volume of distribution
0.18 L/kg
Metabolism
1%
Elimination
95%
[L31858]…
Clearance
110-116 mL/min
[L31858]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
It was first patented in 1957[A230108] and received its initial US approval in 1986.[L31858]
[L31883]
Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.
[L31853]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 106 interactions
[L31853][L31858]
Off-target antagonism of GABA(A) receptors may be associated with the development of convulsions and hyperexcitability following tranexamic acid administration[A229383] - the risk appears higher with improper administration or administration during cardiovascular surgery.[L31883] Consider EEG monitoring of patients with a history of seizure.
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L31858]
The Cmax and Tmax following multiple oral doses (1300 mg three times daily x 5 days) were 16.41 mcg/mL and 2.5 h, respectively.
[L31858]
[L31858]
[L31858]
[L31858]
Tranexamic acid distributes into cerebrospinal fluid and the aqueous humor of the eye at concentrations approximately 1/10th of typical plasma concentrations. Tranexamic acid is also able to cross the placenta, found in cord blood at concentrations equivalent to maternal plasma concentrations.
[L31858]
[L31858]
[L31858]
The rate of excretion is dependent on the route of administration - approximately 90% of an intravenously administered dose is excreted within 24 hours whereas only 39% of an orally administered dose is excreted within the same time frame.
[L31883]
[L31858]
Proteins and enzymes this drug interacts with in the body
PMID:6447255
Cleavage of fibronectin and laminin leads to cell detachment and apoptosis.
Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells
Involved compounds
ATC B02AA02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Tranexamic acid
Additional database identifiers
Drugs Product Database (DPD)
1988
ChemSpider
10482000
BindingDB
50428067
PDB
AMH
ZINC
ZINC000100071256
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9071
GenAtlas
PLG
GeneCards
PLG
GenBank Gene Database
X05199
GenBank Protein Database
387026
Guide to Pharmacology
2394
UniProt Accession
PLMN_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q418666), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.